Search Results - "Dellarocca, Steven"

Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers by Sun, Kaiming, Atoyan, Ruzanna, Borek, Mylissa A, Dellarocca, Steven, Samson, Maria Elena S, Ma, Anna W, Xu, Guang-Xin, Patterson, Troy, Tuck, David P, Viner, Jaye L, Fattaey, Ali, Wang, Jing

“…Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and…”
Get full text

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling by CHANGGENG QIAN, LAI, Cheng-Jung, ZIFCAK, Brian, ANNA WAI SEE MA, DELLAROCCA, Steven, BOREK, Mylissa, ZHAI, Hai-Xiao, XIONG CAI, VOI, Maurizio, RUDI BAO, WANG, Da-Gong, JING WANG, XU, Guang-Xin, ATOYAN, Ruzanna, HUI QU, LING YIN, SAMSON, Maria

“…Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically…”
Get full text

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity by LAI, Cheng-Jung, RUDI BAO, ZIFCAK, Brian, XU, Guang-Xin, DELLAROCCA, Steven, ZHAI, Hai-Xiao, XIONG CAI, MUNGER, William E, KEEGAN, Mitchell, PEPICELLI, Carmen V, CHANGGENG QIAN, XU TAO, JING WANG, ATOYAN, Ruzanna, HUI QU, WANG, Da-Gong, LING YIN, SAMSON, Maria, FORRESTER, Jeffrey

“…Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers. However, due to the heterogeneous and dynamic nature…”
Get full text

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy by Bao, Rudi, Lai, Cheng-Jung, Qu, Hui, Wang, Dagong, Yin, Ling, Zifcak, Brian, Atoyan, Ruzanna, Wang, Jing, Samson, Maria, Forrester, Jeffrey, DellaRocca, Steven, Xu, Guang-Xin, Tao, Xu, Zhai, Hai-Xiao, Cai, Xiong, Qian, Changgeng

“…Purpose: We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique pharmacologic properties and…”
Get full text

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer by Bao, Rudi, Lai, Cheng-Jung, Wang, Da-Gong, Qu, Hui, Yin, Ling, Zifcak, Brian, Tao, Xu, Wang, Jing, Atoyan, Ruzanna, Samson, Maria, Forrester, Jeffrey, Xu, Guang-Xin, DellaRocca, Steven, Borek, Mylissa, Zhai, Hai-Xiao, Cai, Xiong, Qian, Changgeng

“…CUDC-305 is a heat shock protein 90 (HSP90) inhibitor of the novel imidazopyridine class. Here, we report its activities in non–small cell lung cancer (NSCLC)…”
Get full text

Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model by Booher, Robert, Dellarocca, Steven, Atoyan, Ruzanna, Borek, Mylissa, Samson, Maria Elena S., Tuck, David

“…IRAK4 kinase activity is required for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid cell types…”
Get full text

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL by Sun, Kaiming, Atoyan, Ruzanna, Borek, Mylissa A, Dellarocca, Steven, Rhyasen, Garrett, Fattaey, Ali, Tuck, David P

“…CUDC-907 is a first-in-class, oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. Specifically, CUDC-907 is designed to inhibit HDACs…”
Get full text

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma by Booher, Robert N, Nowakowski, Grzegorz S., Patel, Krish, Lunning, Matthew A., Samson, Maria Elena S., Atoyan, Ruzanna, Ma, Anna W, Xu, Guang-Xin, Dellarocca, Steven, Modafferi, Holly, Borek, Mylissa, Zhang, Zhidong, Parker, Jefferson, Whitney, Duncan, Wang, Hongwei, Tuck, David P, Younes, Anas

“…Background: IRAK4 kinase activity is required for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid…”
Get full text

Abstract 5502: IAP inhibitor CUDC-427 induces tumor regression or stasis in preclinical models of B cell lymphoma by Tian, Ze, Sun, Kaiming, Patterson, Troy, Atoyan, Ruzanna, Borek, Mylissa, Samson, Maria, Hantzis, Brianne, Ma, Anna W., Dellarocca, Steven, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Evasion from apoptosis is a characteristic of human cancers. The family of Inhibitor of Apoptosis (IAP) proteins plays a pivotal role in apoptosis,…”
Get full text

Abstract 4634: Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies by Sun, Kaiming, Atoyan, Ruzanna, Borek, Mylissa A., Dellarocca, Steven, Samson, Maria E., Ma, Anna W., Xu, Guangxin, Patterson, Troy, Tuck, David P., Viner, Jaye L., Fattaey, Ali, Wang, Jing

“…Abstract MYC family genes are among the most frequently deregulated oncogenic drivers in human cancer. Pharmacologic inhibition of HDAC activity and blockade…”
Get full text

Abstract 917: Post-treatment changes in levels of TNF family ligands and XIAP may predict sensitivity to IAP antagonist CUDC-427 by Atoyan, Ruzanna, Samson, Maria Elena S., Hantzis, Brianne, Ma, Anna W., Yin, Ling, Borek, Mylissa, Dellarocca, Steven, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Inhibitors of apoptosis (IAP) proteins are a novel target for cancer therapy. Antagonists of IAP proteins have been shown to synergize with TNF…”
Get full text

Abstract 4324: Predictive biomarker signatures for IAP inhibitor CUDC-427 by Sun, Kaiming, Tian, Ze, Zhang, Qi, Samson, Maria, Atoyan, Ruzanna, Borek, Mylissa, Dellarocca, Steven, Zifcak, Brian, Patterson, Troy, Ma, Anna W., Xu, Guangxin, Wick, Michael J., Rickles, Richard, Wang, Jing

“…Abstract The Inhibitors of Apoptosis (IAP) are a family of functionally related proteins that serve as endogenous regulators of apoptosis. The frequent…”
Get full text

Abstract 1879: Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies by Ma, Anna W., Atoyan, Ruzanna, Younes, Anas, Flinn, Ian W., Oki, Yasuhiro, Copeland, Amanda, Berdeja, Jesus G., Laliberte, Robert, Viner, Jaye, Samson, Maria Elena S., Dellarocca, Steven, Yi, Ling, Borek, Mylissa, Zifcak, Brian, Xu, Guangxin, Wang, Jing

“…Abstract Histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K)/AKT pathway are promising therapeutic targets in hematologic cancers and…”
Get full text

CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies by Wang, Jing, Pursell, Natalie, Ma, Anna, Atoyan, Ruzanna, Samson, Maria, Borek, Mylissa, DellaRocca, Steven, Yin, Ling, Wang, Da-gong, Zifcak, Brian, Xu, Guang-xin, Voi, Maurizio, Lai, Cheng-Jung

“…Histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K) inhibitors have each emerged as promising anti-cancer therapeutics that may target not only…”
Get full text

Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models by Rudi, Bao, Wang, Dagong, Qu, Hui, Yin, Ling, Zifcak, Brian, DellaRocca, Steven, Xu, Guang-Xin, Borek, Mylissa, Samson, Maria, Atoyan, Ruzanna, Poli, Anne, Wang, Jing, Zhai, Hai-Xaio, Lai, Cheng-Jung, Pepicelli, Carmen, Cai, Xiong, Qian, Changgeng

“…Abstract Recent evidence indicates that both PI3K-Akt-mTOR signaling pathway and HDAC are validated targets in hematological cancers. In order to overcome…”
Get full text

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models by Bao, Rudi, Wang, Dagong, Qu, Hui, Wang, Jing, Atoyan, Ruzanna, Xu, Guang-Xin, Yin, Ling, Zifcak, Brian, Borek, Mylissa, Samson, Maria, Ma, Anna, DellaRocca, Steven, Zhai, Hai-Xiao, Lai, Cheng-Jung, Pepicelli, Carmen, Cai, Xiong, Qian, Changgeng

“…Abstract In order to achieve cancer signaling network disruption and overcome primary and/or secondary resistance to standard of care agents in hematologic…”
Get full text

Abstract 3249: Design and synthesis of imidazopyridine derivatives as novel HSP90 inhibitors for the treatment of cancer by Cai, Xiong, Zhai, Hai-Xiao, Wang, Jing, Samson, Maria, Atoyan, Ruzanna, Forrester, Jeffrey, Qu, Hui, Yin, Ling, Wang, Dagong, Zifcak, Brian, DellaRocca, Steven, Xu, Guang-Xin, Lai, Cheng-Jung, Bao, Rudi, Simonin, Marie-Paule, Keegan, Mitchell, Pepicelli, Carmen V., Qian, Changgeng

“…Abstract The molecular chaperone heat shock protein 90 (HSP90) is involved in folding and stabilization of a wide range of client proteins, including key…”
Get full text

Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models by Bao, Rudi, Wang, Dagong, Qu, Hui, Yin, Ling, Xu, Guang-Xin, DellaRocca, Steven, Borek, Mylissa, Atoyan, Ruzanna, Forrester, Jeffrey, Samson, Maria, Wang, Jing, Zhai, Hai-Xaio, Chan, Mendy, Lai, Cheng-Jung, Cai, Xiong, Qian, Changgeng

“…Abstract Recent evidence indicates that PI3K-Akt-mTOR signaling plays a crucial role in the development and progression of hematologic cancers. Therefore,…”
Get full text

Abstract 2619: Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR and HER2 inhibitor, on preventing drug resistance and tumor metastasis by Wang, Jing, Selmi, Kader, Samson, Maria, Forrester, Jeffrey, Atoyan, Ruzanna, Qu, Hui, Yin, Ling, Wang, Da-Gong, Zifcak, Brian, Borek, Mylissa, DellaRocca, Steven, Bao, Rudi, Zhai, Hai-Xiao, Cai, Xiong, Qian, Changgeng, Savagner, Pierre, Lai, Cheng-Jung

“…Abstract CUDC-101 is a novel small-molecule multi-target anti-cancer agent currently in Phase Ib clinical trial, which targets histone deacetylase (HDAC),…”
Get full text

Abstract 4469: Antitumor activity of a single small molecule agent targeting Pi3K/mTor and HDAC by Bao, Rudi, Lai, Cheng-Jung, Wang, Dagong, Qu, Hui, Yin, Ling, Zifcak, Brian, Tao, Xu, Wang, Jing, Zhai, Hai-Xiao, Xu, Guang-Xin, Borek, Mylissa, Atoyan, Ruzanna, Samson, Maria, Forrester, Jeffrey, Dellarocca, Steven, Cai, Xiong, Qian, Changgeng

“…Abstract Activation of the PI3K-Akt-mTOR signaling pathway plays a crucial role in cancer development and progression. Inhibition of this pathway has been…”
Get full text